Shahid Akhter, editor, ETHealthworld spoke to Dr Ivo Petrov, Medical Director and Head of Cardiology, City Clinic, Sofia, Bulgaria to know more about the protocols in CVD management in Bulgaria.
Global trends in cardio-vascular diseases
All over the world cardio-vascular diseases is the number one killer disease. We are collaborating very well between the societies and among our speciality – cardiology and cardiovascular disease treatment and to interchange very good ideas and technology.
Trends in CVD monitoring and diagnosis
It is increasing, as now I can see the patient’s real time data online. In a very tiny gadget that shows the ECG, the blood pressure, the saturation, the heart rate, so the physiological parameters that are important to know the people at risk and their situation at that moment. So this is probably the most important collaboration between the human brain and the technology. Gathering more big data in cardiovascular disease will help us to diagnose and treat the patients on time in order to decrease both the mortality, morbidity and to get more advantages in future.
Public Private Partnership
The collaboration between the public and the private is extremely important for example in Bulgaria both private and public hospitals have the right to get a contract with the National Health Fund. This is giving equal rights and equal access to older population to healthcare. So the hybrid system is the best way.
Future of stents
All the implants are very important in the treatment of the cardio vascular diseases. In cardiovascular procedures more than 90 percent of the cases are treated with some implants and it is important because there are millions of people worldwide that are receiving stents so, the technology of stents are improving in material, metal, bioabsorbable stents. We are in the search now to improve the result of future stents and I am sure that in the next several years we are going to have a burning piece of news.
Choice of stents
It is up-to-date and very modern to speak about the individualised medicine, there is no one stent that will fit in everybody and because of that we have multiple choices. So there are companies producing stents that are good for long collisions, calcified collisions and for big calcifications. We are choosing proper stent for every single patient for clinical and anatomical conditions and of course following the results of the scientific trails. So it is very important to have heart team decision and have a variety of stents on the shelf in order to choose for the patient the best one.
